Discovery and development of purine-scaffold Hsp90 inhibitors

Expert Opinion on Drug Discovery

Volumn 3, Issue 1, 2008, Pages 99-114

  Chiosis, Gabriela ^a   Kang, Yanlong ^a   Sun, Weilin ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cancer; Hsp90; Neurodegeneration; Purine scaffold

Indexed keywords

17 DIMETHYLETHYLAMINE 17 DEMETHOXYGELDANAMYCIN; 8 BENZOTHIAZOLE PURINE DERIVATIVE; 8 BENZYL PURINE DERIVATIVE; 8 PHENYLSULFANYL PURINE DERIVATIVE; 9 BENZYL PURINE DERIVATIVE; ACIVICIN; ADENOSINE TRIPHOSPHATASE; ANSAMYCIN DERIVATIVE; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC ANTIBIOTIC; BIIB 021; CNF 2024; COLCHICINE DERIVATIVE; CYTOCHROME P450; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ETOPOSIDE; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; ISOXAZOLE DERIVATIVE; PROTEIN KINASE B; PROTEIN MUTL; PURINE DERIVATIVE; RAF PROTEIN; TANESPIMYCIN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VER 50589; VINCA ALKALOID;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL CULTURE; CANCER INHIBITION; CELL METABOLISM; CLINICAL TRIAL; DEGENERATIVE DISEASE; DOWN REGULATION; DRUG BINDING SITE; DRUG BIOAVAILABILITY; DRUG CLASSIFICATION; DRUG DESIGN; DRUG DOSE ESCALATION; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; LIVER TOXICITY; MALIGNANT NEOPLASTIC DISEASE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SYNTHESIS INHIBITION; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 38849117688     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.3.1.99     Document Type: Review

References (80)

1. Xu W, Neckers L. Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells. Clin Cancer Res 2007; 13:1625-9
2. Powers MV, Workman P. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr Relat Cancer 2006;13(Suppl 1):S125-S135
3. Kamal A, Thao L, Sensintaffar J, et al. Therapeutic and diagnostic implications of Hsp90 activation. Trends Mol Med 2004;10:283-90
4. Chiosis G. Modulating chaperones in transformed systems - a focus on Hsp90 and cancer. Expert Opin Ther Targets 2006; 10:37-50
5. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005; 10:761-72
6. Prodromou C, Pearl LH. Structure and functional relationships of Hsp90. Curr Cancer Drug Targets 2003;3:301-23
7. Chene P. ATPases as drug targets: learning from their structure, Nat Rev Drug Discov 2002;1:665-73
8. Neckers L, Schulte TW, Mimnaugh E. Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity Invest New Drugs 1999;17:361-73
9. Whitesell L, Shifrin SD, Schwab G, Neckers LM. Benzoquinonoid ansamycins possess selective tumoricidal activity unrelated to src kinase inhibition. Cancer Res 1992;52:1721-8
10. Stebbins CE, Russo AA, Schneider C, et al. Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 1997;89:239-50
11. Roe SM, Prodromou C, O'Brien R, et al. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J Med Chem 1999;42:260-6
12. Schneider C, Sepp-Lorenzino L, Nimmesgern E, et al. Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90. Proc Natl Acad Sci USA 1996;93:14536-41
13. Mimnaugh EG, Chavany C, Neckers L. Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J Biol Chem 1996;271:22796-801
14. Connell P, Ballinger CA, Jiang J, et al. The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. Nat Cell Biol 2001;3:93-6
15. Schulte TW, Neckers LM. The benzoquinone ansamycin 17-allylamino- 17-demethoxygeldanamycin binds to Hsp90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol 1998;42:273-9
16. Smith V, Sausville EA, Camalier RF, et al. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models. Cancer Chemother Pharmacol 2005;56:126-37
17. Banerji U, O'donnell A, Scurr M, et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 2005;23:4152-61
18. Goetz MP, Toft D, Reid J, et al. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 2005;23:1078-87
19. Grem JL, Morrison G, Guo XD, et al. Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol 2005;23:1885-93
20. Modi S, Stopeck A, Gordon MS, et al. The combination of trastuzumab and tanespimycin (KOS 953, 17-AAG) is safe and active in trastuzumab-refractory HER2 overexpressing breast cancer: a Phase 1 dose-escalation study. J Clin Oncol 2007 (In Press)
21. Richardson PG, Chanan-Khan A, Lonial S, et al. Tanespimycin (T) + bortezomib (BZ) in multiple myeloma (MM): Pharmacology, safety and activity in relapsed/refractory (rel/ref) patients (Pts). J Clin Oncol, ASCO Annual Meeting Proceedings Part I. 2007;25(18S Suppl):3532
22. Saif MW, Erlichman C, Dragovich CT, et al. Phase I study of CNF1010 (lipid formulation of 17-(allylamino)-17-demethoxygeldanamycin: 17-AAG) in patients with advanced solid tumors. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2006;24(18S Suppl):10062
23. Lancet J, Baer MR, Gojo I, et al. Phase 1, pharmacokinetic (PK) and pharmacodynamic (PD) study of intravenous alvespimycin (KOS-1022) in patients with refractory hematological malignancies. Blood 2006; 108:Abstract 1961
24. Cysyk RL, Parker RJ, Barchi JJ Jr, et al. Reaction of geldanamycin and C17-substituted analogues with glutathione: product identifications and pharmacological implications. Chem Res Toxicol 2006;19:376-81
25. Egorin MJ, Rosen DM, Wolff JH, et al. Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations. Cancer Res 1998;58:2385-96
26. Kelland LR, Sharp SY, Rogers PM, et al. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst 1999;91:1940-9
27. Zhang H, Neely LS, Yang Y-C, Burrows FJ. Influence of muldidrug resistance proteins on the antitumor activity of natural and synthetic Hsp90 inhibitors. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications, 2005. Philadelphia, USA. Abstract C39
28. Guo W, Reigan P, Siegel D, et al. Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition. Cancer Res 2005;65:10006-15
29. Chiosis G, Caldas Lopes E, Solit D. Hsp90 inhibitors - a chronicle from geldanamycin to today's agents. Curr Opin Investig Drugs 2006;6:534-41
30. Chiosis G, Timaul MN, Lucas B, et al. a small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells. Chem Biol 2001;8:289-99
31. Sloan Kettering Institute Cancer Res. Small molecule composition for binding to Hsp90. WO0236075; 2002
32. Wright L, Barril X, Dymock B, et al. Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms. Chem Biol 2004;6:775-85
33. Chiosis G, Lucas B, Shtil A, et al. Development of a purine-based novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinase. Bioorg Med Chem 2002; 10:3555-64
34. Conforma Therapeutics Corp. Purine analogues having Hsp90 inhibiting activity. WO03037860; 2003
35. Vilenchik M, Solit D, Basso A, et al. Targeting wide-range oncogenic transformation via PU24FCI, a specific inhibitor of tumor Hsp90. Chem Biol 2004; 11:787-97
36. Dymock B, Barril X, Beswick M, et al. Adenine derived inhibitors of the molecular chaperone HSP90-SAR explained through multiple X-ray structures. Bioorg Med Chem Lett 2004;2:325-8
37. Biamonte MA, Shi J, Hong K, et al. Orally active purine-based inhibitors of the heat shock protein 90. J Med Chem 2006;49:817-28
38. He H, Zatorska D, Kim J, et al. Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90. J Med Chem 2006;49:381-90
39. Sloan Kettering Institute Cancer Res. Small molecule Hsp90 inhibitors. WO2006084030; 2006
40. Llauger L, He H, Kim J, et al. 8-Arylsulfanyl and 8-arylsulfoxyl adenine derivatives as inhibitors of the heat shock protein 90. J Med Chem 2005;48:2892-905
41. Immormino RM, Kang Y, Chiosis G, Gewirth DT. Structural and Quantum Chemical Studies of 8-aryl-sulfanyl adenine class Hsp90 inhibitors. J Med Chem 2006;49:4953-60
42. Zhang L, Fan J, Vu K, et al. 7′-substituted benzothiazolothio- and pyridinothiazolothio-purines as potent heat shock protein 90 inhibitors. J Med Chem 2006;49:5352-62
43. Kasibhatla SR, Hong K, Biamonte MA, et al. Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity. J Med Chem 2007;50:2767-78
44. Conforma Therapeutics Corp. 2-Aminopurine analogs having HSP90-inhibiting activity. US2007185064; 2007
45. Conforma Therapeutics Corp. 7,9-Dihydro-purin-8-one and related analogs of Hsp90-inhibitors. WO2007092496; 2007
46. Kamal A, Thao L, Sensintaffar J, et al. A high affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003;425:407-10
47. Rodina A, Vilenchik M, Moulick K, et al. Selective compounds define Hsp90 as a major inhibitor of apoptosis in small cell lung cancer. Nat Chem Biol 2007;8:498-507
48. Sloan Kettering Institute Cancer Res. Assays for detection of bioactive compounds that interact with heat shock protein 90. WO2005012482; 2005
49. Conforma Therapeutics Corp. Assays and implements for determining and modulating hsp90 binding activity. US074457; 2005
50. Caldas-Lopes EM, Kim J, Rondina A, et al. Targeting basal-like breast cancer via purine-scaffold Hsp90 inhibitors. American Association for Cancer Research 98th Annual Meeting, 2007; Los Angeles, USA. Abstract 3964
51. Ciombor KK, Rocha Lima CM. Management of small cell lung cancer. Curr Treat Options Oncol 2006;7:59-68
52. Banerjee S, Reis-Filho JS, Ashley S, et al. Basal-like breast carcinoma: clinical outcome and response to chemotherapy. J Clin Pathol 2006;59:729-35
53. She QB, Solit DB, Ye Q, et al. The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell 2005;8:287-97
54. Eiseman JL, Lan J, Lagattuta TF, et al. Pharmacokinetics and pharmacodynamics of 17-demethoxy 17- (2-dimethylamino)ethyl]amino] geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts. Cancer Chemother Pharmacol 2005;55:21-32
55. Banerji U, Walton M, Raynaud F, et al. Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models. Clin Cancer Res 2005; 11:7023-32
56. Sydor JR, Normant E, Pien CS, et al. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc Natl Acad Sci USA 2006;103(46):17408-13
57. Sharp SY, Prodromou C, Boxall K, et al. Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues. Mol Cancer Ther 2007;6:1198-211
58. Hollingshead M, Alley M, Burger AM, et al. In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative. Cancer Chemother Pharmacol 2005;56:115-25
59. Kosik KS, Shimura H. Phosphorylated tau and the neurodegenerative foldopathies. Biochim Biophys Acta 2005;1739:298-310
60. Luo W, Dou F, Rodina A, et al. Roles of heat shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies. Proc Nad Acad Sci USA 2007;104:9511-16 Provides a novel principle governing both cancer and neurodegenerative diseases.
61. Dickey CA, Kamal A, Lundgren K, et al. The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J Clin Invest 2007; 117:648-58
62. Waza M, Adachi H, Katsuno M, et al. 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nat Med 2005;11:1088-95
63. Kantarjian H. A Phase I dose escalation study of CNF2024 for ZAP-70 positive CLL. MD Anderson Leuk Insights Newslett 2005; 10:3
64. MD Anderson Cancer Center. A Phase I, dose-escalation study of CNF2024 administered orally to patients with B-cell chronic lymphocytic leukemia (CLL). 2005. Available from: URL: http://utm-ext01a.mdacc.tmc.edu/dept/ prot/clinicaltrialswp.nsf/Index/2005-0452 [last accessed November 21, 2007]
65. Clinical Trials.gov. A Phase 1, dose-escalation study of CNF2024 administered orally to patients with B-cell chronic lymphocytic leukemia (CLL). 2006. Available from: URL: http://clinicaltrials.gov/ct/show/ NCT00344786?order=1 [last accessed November 21, 2007]
66. ClinicalTrials.gov. A Phase 1, multicenter, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of CNF2024 administered orally twice weekly for three weeks of a four week course or twice weekly for four weeks of a four week course to patients with advanced solid tumors. 2006. Available from: URL: http://clinicaltrials.gov/ct/show/NCT00345189?order=3 [Last accessed November 21, 2007]
67. A Phase 1 open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of CNF2024 as a single-agent treatment in subjects with HER2- advanced breast cancer or in combination with trastuzumab in subjects with HER2+ advanced breast cancer. 2007. Available from: URL: http://clinicaltrials.gov/ct/show/ NCT00412412;jsessionid=40744D912A141130AFA975B63DF7807B?order=39 [last accessed November 21, 2007]
68. Lundgren K, Zhang H, Kamal A, et al. BIIB021 is a small molecule inhibitor of the heat shock protein, Hsp90, that shows potent anti-tumor activity in preclinical models. AACR/NCI/EORTC Molecular Targets Meeting; 2007; San Francisco, USA. Abstract B-161
69. McDonald E, Jones K, Brough PA, et al. Discovery and development of pyrazole-scaffold Hsp90 inhibitors. Curr Top Med Chem 2006;6:1193-203
70. Brough P, Massey A, Drysdale M, et al. NVP-AUY922/VER-52296: a novel 3,4 diarylisoxazole Hsp90 chaperone inhibitor discovered via structure-based drug design. AACR/NCI/EORTC Molecular Targets Meeting; 2007; San Francisco, USA. Abstract B-281
71. Serenex. Overview of Serenex's Hsp90 program. 2007. Available from: URL: http://www.serenex.com/Page 106 [Last accessed November 24, 2007]
72. Chan CT, Paulmurugan R, Gheysens OS, Kim J, Chiosis G, Gambhir SS. Molecular imaging of the efficacy of heat shock protein 90 inhibitors in living subjects. Cancer Res 2007 (In Press)
73. Sreedhar AS, Kalmar E, Csermely P, Shen Y-F. Hsp90 isoforms: function, expression and clinical importance. FEBS Lett 2004;562:11-15
74. Millson SH, Truman AW, Racz A, et al. Expressed as the sole Hsp90 of yeast, the alpha and beta isoforms of human Hspg0 differ with regard to their capacities for activation of certain client proteins, whereas only Hsp90beta generates sensitivity to the Hsp90 inhibitor radicicol. FEBS J 2007;274:4453-63
75. Eustace BK, Sakurai T, Stewart JK, et al. Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness. Nat Cell Biol 2004;6:507-14
76. Madden T-A, Pumford S, Barrow D, et al. Development of acquired resistance to 17(Allylamino)-17-demethoxygeldanamycin (17-AAG) in hormone refractory breast cancers in vitro American Association for Cancer Research 96th Annual Meeting; 2005; Anaheim, USA. Abstract LB-267
77. Soga S, Shiotsu Y, Akinaga S, Sharma SV. Development of radicicol analogues. Curr Cancer Drug Targets 2003;3:359-69
78. Bagatell R, Paine-Murrieta GD, Taylor CW, et al. Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents. Clin Cancer Res 2000;6:3312-18
79. Ficker E, Dennis AT, Wang L, Brown AM Role of the cytosolic chaperones Hsp70 and Hsp90 in maturation of the cardiac potassium channel HERG. Circ Res 2003;92:e87-e100
80. Price JT, Quinn JM, Sims NA, et al. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line. Cancer Res 2005;65:4929-38